Viracor Eurofins Baloxavir marboxil (Xofluza) Influenza A Antiviral Resistance PCR

Viracor Eurofins has launched its test for resistance to the antiviral Xofluza (baloxavir marboxil). The Baloxavir marboxil (Xofluza) Influenza A Antiviral Resistance PCR detects I38T/M/F mutations in H3N2 and 2009 H1N1 strains of influenza A and aids in evaluating resistance to the drug developed by Shionogi and Roche. Results can be available to healthcare providers within eight to 12 hours from the receipt of nasopharyngeal swab at Viracor's lab, the company said.